Dietary ω-3 polyunsaturated fatty acid intake improves skeletal muscle mass in patients with metabolic dysfunction-associated fatty liver disease: A nationwide cross-sectional study Li-Zhan Bie, Chao Wu, Jia-Lu Wang World Journal of Hepatology.2025;[Epub] CrossRef
Managing MASLD Through Preventive Hepatology: Integrating Policy Reform, Public Health and Personalised Care Zobair M. Younossi, Vincent Wai‐Sun Wong, Emmanuel A. Tsochatzis, Laurent Castera, Michael Betel, Linda Henry, Shira Zelber Sagi Liver International.2025;[Epub] CrossRef
Steatotic liver disease, MASLD and risk of chronic kidney disease Josh Bilson, Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher Diabetes & Metabolism.2024; 50(1): 101506. CrossRef
Impact of MAFLD criteria on postoperative recurrence of non-B, non-C HCC Yusuke Johira, Takashi Nakahara, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Shiro Oka European Journal of Gastroenterology & Hepatology.2024; 36(4): 430. CrossRef
Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice Paul N Brennan, Oliver D Tavabie, Wenhao Li, Thomas Marjot, Lynsey Corless, Jonathan A Fallowfield, Helen Jarvis, Dina Mansour, Stuart McPherson, William Rosenberg, Karen Rockell, Jeremy Tomlinson, Andrew Yeoman, Emmanuel A Tsochatzis, John F Dillon, Will The Lancet Gastroenterology & Hepatology.2024; 9(6): 577. CrossRef
Does an Aspirin a Day Take the MASLD Away? Amedeo Lonardo, Ming-Hua Zheng Advances in Therapy.2024; 41(7): 2559. CrossRef
Neuroimmune modulation in liver pathophysiology Ju Zou, Jie Li, Xiaoxu Wang, Daolin Tang, Ruochan Chen Journal of Neuroinflammation.2024;[Epub] CrossRef
Letter regarding “Waiting for the changes after the adoption of steatotic liver disease” Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon Clinical and Molecular Hepatology.2023; 30(1): 118. CrossRef
First
Prev
